Latest News and Press Releases

- Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Study - - Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b study...

SPR announces new distribution agreement with Veteran's Health Medical Supply to expand access to SPRINT PNS for veterans

SPR announces publication of four-year follow-up data demonstrating significant and sustained low back pain relief following SPRINT PNS treatment.

ATLANTA, April 11, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on developing new medicines to treat pain...

ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biopharmaceutical company focused on advancing first-in-class,...

SPR Announces Presentation of Four Abstracts Featuring the SPRINT® PNS System at NANS 2025

Ben Austin, CFO and COO of SPR® Therapeutics, Named to Crain’s Cleveland Business 40 Under 40 List.

SPR Therapeutics announced the presentation of five abstracts at the ASPN Annual Conference including four-year data on SPRINT PNS.

New Publication on Percutaneous PNS in the Management of Chronic Pain Highlights Consistent, Sustained Relief of Pain Across Multiple Targets

SPR Therapeutics Announces $85 Million in Additional Funding to Advance Commercial Expansion of SPRINT PNS System.